Enasidenib (AG-221) Maintenance Post Allogeneic HCT in Patients With IDH2 Mutation

Summary

This phase II trial studies the side effects of using enasidenib as maintenance therapy in treating patients with acute myeloid leukemia with IDH2 mutation following donor stem cell transplant. Enasidenib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

Timeline

Start

2019-07-11

Primary completion

2027-01-11

Completion

2027-01-11

Publications

• Shallis RM, Podoltsev NA. Maintenance therapy for acute myeloid leukemia: sustaining the pursuit for sustained remission. Curr Opin Hematol. 2021 Mar 1;28(2):110-121. doi: 10.1097/MOH.0000000000000637.

Drugs

Indications